Chimeric antigen receptors (CAR) are recombinant receptors that provide both antigen-binding and T-cell-activating functions. A multitude of CARs has been reported over the past decade, targeting an array of cell surface tumor antigens. Their biologic functions have dramatically changed following the introduction of tripartite receptors comprising a costimulatory domain, termed second-generation CARs. These have recently shown clinical benefi t in patients treated with CD19-targeted autologous T cells. CARs may be combined with costimulatory ligands, chimeric costimulatory receptors, or cytokines to further enhance T-cell potency, specifi city, and safety. CARs represent a new class of drugs with exciting potential for cancer immunotherapy.
INTRODUCTION
Chimeric antigen receptors (CAR) are recombinant receptors for antigen, which, in a single molecule, redirect the specifi city and function of T lymphocytes and other immune cells. The general premise for their use in cancer immunotherapy is to rapidly generate tumor-targeted T cells, bypassing the barriers and incremental kinetics of active immunization ( 1, 2 ) . Once expressed in T cells, the CAR-modifi ed T cells acquire supraphysiologic properties and act as "living drugs" that may exert both immediate and long-term effects. The engineering of CARs into T cells requires T cells to be cultured to allow for transduction and expansion. The transduction may use a variety of methods, but stable gene transfer is required to enable sustained CAR expression in clonally expanding and persisting T cells. In principle, any cell surface molecule can be targeted through a CAR, thus overriding tolerance to self-antigens and the antigen recognition gaps in the physiologic T-cell repertoire that limit the scope of T-cell reactivity.
Various T cell subsets, as well as T-cell progenitors and other immune cells, such as natural killer cells, can be targeted with a CAR. Redirecting immune reactivity toward a chosen antigen is not the only purpose of smarter CARs, which are designed to accomplish much more than to target and initiate T-cell activation. CARs with different strengths and quality of signaling have the potential to modulate T-cell expansion and persistence as well as the strength of T-cell activation within the tumor microenvironment, features that dramatically alter the effi cacy and safety of tumor-targeted T cells. In this regard, CARs provide a broader range of functional effects than transduced T-cell receptors (TCR), wherein strength of signaling, which is for the most part determined by the TCR's affi nity for antigen, is the principal determinant of T-cell fate. CARs and TCRs have their respective advantages and disadvantages (1) (2) (3) (4) . Although the fl exibility and "dynamic range" of CARs is attractive, current CARs are limited to recognizing cell surface antigens, whereas TCRs recognize both cell surface and intracellular proteins. CARs, however, do not require antigen processing and presentation by HLA and are therefore more broadly applicable to HLA-diverse patient populations. We discuss here the targeting and signaling properties of CARs, focusing on their effects on T-cell specifi city, potency, and safety. Other general aspects of adoptive T-cell therapy that apply not only to the use of CARs but also to other T-cell therapies as well, including T-cell expansion methodologies, T-cell subset selection, and host conditioning, are beyond the scope of this review. Owing to the extraordinary potential of T-cell REVIEW engineering and the modular nature of their structure, CARs are rapidly evolving and show great promise for their successful use in a wide range of immunotherapies.
CAR TARGETING
CARs are recombinant receptors that typically target native cell surface antigens ( 4 ) . Unlike the physiologic TCR, which engages HLA-peptide complexes, CARs engage molecules that do not require peptide processing or HLA expression to be recognized. CARs therefore recognize antigen on any HLA background, in contrast to TCRs, which need to be matched to the haplotype of the patient. Furthermore, CARs can target tumor cells that have downregulated HLA expression or proteasomal antigen processing, 2 mechanisms that contribute to tumor escape from TCR-mediated immunity ( 5 ) . Another feature of the broad applicability of CARs is their ability to bind not only to proteins but also to carbohydrate and glycolipid structures, again expanding the range of potential targets. A survey of antigens targeted to date by CARs is shown in Table 1 .
The moieties used to bind to antigen fall in 3 general categories: (i) single-chain variable fragment (scFv) derived from antibodies; (ii) Fab s fragment antigen-binding (Fab) selected from libraries; or (iii) nature ligands that engage their cognate receptor (see Fig. 1 , fi rst-generation CARs). Successful examples in each of these categories (too many to cite) have been reported ( Table 1 ) . scFvs derived from murine immunoglobulins are commonly used, as they are easily derived from well-characterized monoclonal antibodies. However, they may prove to be more immunogenic than Fabs derived from human libraries or invariant human ligands.
The rules for selecting optimal epitopes for CAR targeting are still little known. The position of the epitope and its distance to the cell surface are expected to affect the binding to the antigen and the optimal formation of T-cell target conjugates and synapses ( 6 ), but little is known about the overall rules governing the optimal epitope selection. Empirical observations indicate that the structure of the "spacer region" between an scFv and the transmembrane region ( Fig.  1 ) can affect CAR specifi city, but no defi nitive principles have yet emerged ( 7 ) . CAR length and protrusion from the T-cell membrane are likely to affect synapse formation. The optimal affi nity of CARs is also little defi ned. Few studies have attempted to address this question, which is of major importance in the case of TCRs ( 8, 9 ) and likely to affect CAR function as well. Informative studies comparing multiple CARs recognizing the same epitope with different affi nities are still lacking. Finally, the effect of antigen density is not yet well defi ned. CARs typically target highly expressed antigens, but little is known about minimum thresholds. It is uncertain whether CARs are as exquisitely sensitive as TCRs ( 9 ) . If not, lesser sensitivity could represent a limitation in their activity against tumors expressing low antigen levels but may also turn into an advantage where avoidance of low-level antigen expression on normal cells is desirable. Thus, the antigenbinding moiety of the CAR is not only a targeting device but also is integral to CAR function, which is not solely defi ned by the signaling components incorporated into the cytoplasmic domain of CAR.
CAR SIGNALING
The fi rst fusion receptors shown to have T-cell-activating potential on their own were chimeric molecules between CD3-ζ or Fc receptor γ and CD8, CD4, CD25, or CD16 ( Fig. 1 , fi rstgeneration CARs), which were shown to initiate phosphatidylinositol and tyrosine kinase pathways together with calcium infl ux in human T-cell leukemias (10) (11) (12) (13) . The addition of a hapten-specifi c scFv derived from a murine antibody to the extracellular portion of such fusions, termed a T-body ( Fig. 1 , fi rst-generation CARs), effectively redirected cytolysis by murine T-cell hybridomas ( 14 ) . Although CD3-ζ chain aggregation is suffi cient to enable lytic activity in CTL lines, it is important to bear in mind that the strength of signal required for cytotoxicity is lower than that needed for other T-cell functions. This likely underscores the limited therapeutic responses reported with activating receptors, the antitumoral effects of which are often confi ned to local administration models ( 15, 16 ) or short-term systemic models ( 17 ) . In transgenic mice, T cells expressing CARs that only comprise an activation domain in their cytoplasmic domain are prone to undergoing anergy ( 18 ) .
Once we could effi ciently transduce human primary T cells (see below), we found that CD3-ζ CARs failed to elicit a robust cytokine response, including interleukin (IL)-2, and support T-cell expansion upon repeated exposure to antigen ( 19 ) . It would take the design of a tripartite fusion receptor, possessing both activating and costimulatory properties ( Fig. 1 , second-generation CARs), to obtain absolute T-cell expansion of human peripheral blood T cells upon repeated exposure to antigen ( 20 ) . Signifi cantly, these essential functions cannot be investigated in leukemic or immortalized T-cell lines ( 21 ) , but only in primary T cells, which CAR investigators have now solidly embraced as the gold standard for evaluating CAR function in vitro or in vivo . Eventually dubbed second-generation CARs, receptors encompassing the 
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CD3-ζ chain, and the cytoplasmic domain of a costimulatory receptor such as CD28, 4-1BB, DAP10, OX40, or ICOS, were eventually reported ( Table 1 ). The superior activity of dual-signaling receptors over the activating-only receptors was observed in several models using mouse or human T cells (22) (23) (24) . The key attribute of dual-signaling receptors is to confer greater strength of signaling and persistence to the T cells, resulting in their overall greater potency. The enhanced persistence imparted by dual-signaling CARs has been confi rmed in patients treated with a mixture of T cells transduced with either a CD28/CD3ζ or CD3ζ-only CAR ( 25 ) . Secondgeneration CARs come in varied confi gurations, but exhaustive comparisons are still lacking. Some CD28 and 4-1BB-based second-generation CARs were compared in animal models, but either one proved to be superior to the other in different contexts. In one study, Carpenito and colleagues ( 26 ) found that two CD28 and 4-1BB-based CD19-specifi c CARs had the same therapeutic activity, but they noted that the T cells expressing the 19-BB CAR accumulated to greater levels over time, possibly in an antigen-independent fashion. This difference was not observed in another model ( 27 ) . More comparative studies are needed to take into account the variability between CARs within any one given category. For example, different CD28/ CD3ζ CARs differ in their ability to elicit IL-2 secretion ( 20 , 28 ) . Furthermore, the location of the targeted epitope, its density, the affi nity of the CAR, and other topologic effects of CAR structure affect CAR signaling, as discussed above. Comparisons will thus need to include multiple representatives of the evaluated categories to reach generalizable conclusions.
A third generation of CARs, encompassing 2 costimulatory domains combined with an activation domain in their cytoplasmic domain ( Fig. 1 , third-generation CARs), has been described, which seems to confer yet greater potency to tumor targeted T cells in some mouse models ( 26, 27 , 29, 30 ) . These more complex structures warrant further study as well. A fi rst clinical study using a CD20-specifi c CD28/4-1BB/CD3ζ did not show dramatic responses ( 31 ) , but this early result should not in any way detract from the potential value of these "triple-decker" CARs. Overall, more investigation is needed to attain a better understanding of optimal CAR signaling to promote sustained T-cell function and survival, preventing premature death, rapid exhaustion, or undue proliferation.
POTENTIATION AND COMPLEMENTATION OF CAR FUNCTION
Costimulatory support can be engineered into T cells in other ways than through a CAR ( Fig. 2 ) . The coexpression of chimeric costimulatory receptors (CCR), costimulatory receptor ligands, and cytokines has been used to modulate the function and/or survival of CAR-transduced T cells.
Costimulatory Ligands
The constitutive expression of costimulatory ligands on the T-cell surface ( Fig. 2 ) 
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contribute to enhanced T-cell activity in this context, which may be useful to enhance adoptive cell therapies using CARor TCR-transduced T cells. The occurrence of costimulatory ligands found on tumor cells is also likely to infl uence the activity of CAR-modifi ed T cells, whether they are activating (e.g., CD80, CD40L, 4-1BBL) or inhibitory (e.g., PD-L1).
Chimeric Costimulatory Receptors
CCRs mimic costimulatory signals but, unlike CARs, do not provide a T-cell activation signal. Their purpose is to provide costimulation, for example, a CD28-like signal ( 33 ) , in the absence of the natural costimulatory ligand on the antigenpresenting cell ( Fig. 2 ) . They thus provide a means for the tumor to direct counterfeit costimulation specifi cally within the tumor microenvironment. CCRs targeting the glycolipid G D2 , MUC16, prostate-specifi c membrane antigen (PSMA), and the α-folate receptor have been described, used in conjunction with a TCR or a CAR to augment T-cell reactivity against the dual-antigen expressing T cells, reinforcing T-cell activation in the absence of natural costimulatory ligands and in an antigen-dependent fashion ( 20 , 33-35 ) . Under particular conditions, CCRs may also be used to improve selective tumor targeting, as further discussed below.
Cytokines
Another approach to enhance the potency of CAR-targeted T cells is to further genetically modify the T cells to secrete proinfl ammatory or proproliferative cytokines. The purpose behind this approach is not only to provide autocrine support to enhance the function, proliferation, and/or persistence of CAR-expressing T cells but also to favorably alter the tumor microenvironment and recruit endogenous innate and cognate immune effectors. The expression of T-cell-encoded cytokines additionally aims to limit the systemic toxicity of many cytokines. Preclinical reports investigating γ c cytokines or IL-12 show great promise for this approach.
T-cell-encoded IL-15 increases the viability and proliferation of human peptide-specifi c T cells despite withdrawal of exogenous IL-2 ( 36 ) . Improved in vitro and in vivo expansion of human Epstein-Barr virus-specifi c cytotoxic T cells following retroviral gene transfer of the IL-2 or IL-15 cDNA has also been reported ( 37 ) . The report of an isolated IL-15-modifi ed CD8 + T-cell clone exhibiting logarithmic proliferation for over 1 year in the absence of exogenous cytokine support cautions against this approach ( 38 ) , although this concern may be mitigated by using a suicide gene to potentially remove T cells via drug-induced apoptosis ( 37 
In an immune-competent syngeneic tumor model, CD19-targeted, CAR-modifi ed T cells expressing IL-12 showed greater effi cacy than CAR-modifi ed T cells alone ( 42 ). Significantly, IL-12-modifi ed T cells eradicated CD19
+ tumors in the absence of any prior conditioning and, additionally, exhibited resistance to regulatory T-cell (Treg) inhibition. In a murine melanoma model, transgenic Pmel-1 CD8 + T cells, or Pmel-1 TCR-transduced murine T cells that were modifi ed to express IL-12, eradicated established tumors with signifi cantly greater potency than T cells expressing the Pmel-1 TCR alone ( 43 ) . Similarly improved outcomes were obtained in tumor-bearing mice treated with IL-12-secreting T cells targeted to tumor by an anti-VEGF receptor-2 CAR ( 44 ). In both latter models, the effect of IL-12 seems to act at least in part by altering myeloid cells in the tumor microenvironment ( 44, 45 ) . The titration of cytokine secretion by T cells is important because of the potential toxicity of elevated systemic levels. One may address this concern by appropriately calibrating promoter strength or through conditional cytokine release following T-cell activation using nuclear factor of activated T cells (NFAT)-inducible promoters ( 46 ) . Using this approach to control cytokine secretion, 2 trials treating metastatic NY-ESO-1 
CARs IN THE CLINIC

The CD19 Paradigm
The most investigated target to date is CD19, an attractive target for CAR-based therapy, as it is present in most B-cell leukemias and lymphomas but not in any normal tissue other than the B cell lineage ( 47, 48 ) . CD19
+ malignancies were the fi rst cancers to be eliminated by CAR-engineered human T cells administered intravenously to systemic tumor-bearing mice ( 49 ) . Successful B-cell tumor eradication was eventually obtained with different CD19 CARs ( 15 , 22-24 ) , paving the way for several ongoing clinical trials. The targeting of CD19 has thus become a paradigm for evaluating CAR technology ( 50 ) . We estimate that at least 50 patients with leukemia or lymphoma have been treated at the time this review is written, 28 of whom were reported from 5 centers in the past year ( 25 , 51-56 ) . The reported clinical outcomes were recently reviewed elsewhere ( 57, 58 ) and are briefl y summarized here. The largest series and most dramatic early results were reported from the NCI, Memorial Sloan-Kettering Cancer Center (MSKCC, New York, NY), and the Abramson Family Cancer Research Institute at the University of Pennsylvania (UPenn, Philadelphia, PA). These clinical trials followed the same overall steps, including a patient T-cell apheresis, retroviral or lentiviral CAR transduction, T-cell expansion, and host conditioning before T-cell infusion. However, the trials differ in several regards, including not only CAR design (same CD28/CD3-ζ dual-signaling domain used at the NCI and MSKCC and 4-1BB/CD3-ζ used at UPenn) but also T-cell manufacturing, conditioning chemotherapy, tumor burden, tumor chemosensitivity, and T-cell dosage, which are reviewed in detail in ref. ( 57 ) 
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1 with marginal zone lymphoma] conditioned with fl udarabine and cyclophosphamide, and further given IL-2 after T-cell infusion. Among the 4 patients with CLL, 1 achieved a complete response (CR) and another stable disease. Four of the 8 treated patients exhibited B-cell aplasias. Brentjens and colleagues reported on 8 patients with CLL and 1 patient with B-cell acute lymphoblastic leukemia (B-ALL), whose disease was resistant to the milder cyclophosphamide conditioning regimen used in 5 of the 8 patients with CLL (the fi rst 3 were given T cells without any prior conditioning; no signifi cant response was obtained). In the CLL cohort, 2 patients had stable disease and 1 patient showed a substantial lymph node reduction. None of the patients with CLL developed B-cell aplasia, in contrast with the patient with relapsed B-ALL ( 52 ). Kalos and colleagues ( 54, 55 ) treated 3 patients with bulky CLL who were conditioned with bendamustine, a highly active agent in such patients. Two of them achieved dramatic, long-lasting CRs. The reasons for the different outcomes in these 15 patients with CLL treated at 3 different centers, which include signifi cant differences in CAR design, conditioning intensity, and the selection of chemosensitive patients, among many variables ( 57 ) , still remain to be elucidated. Taken together, better responses were observed following more active conditioning, resulting in a 25% CR rate in 12 patients with CLL treated with T cells following chemotherapy conditioning. Much will undoubtedly be learned about the role of the CAR and other parameters by comparing biologic and clinical outcomes using similarly manufactured T cells in similarly selected patients.
Solid Tumors
One next frontier for CAR-based therapies is to take on solid tumors. Early attempts with fi rst-generation CARs did not yield very encouraging data ( 59 ), although one recent study targeting the G D2 ganglioside in children with neuroblastoma showed 2 CRs in 13 patients ( 60 ) . Solid tumors present a different set of challenges compared with B-cell malignancies: overall lesser sensitivity to T-cell-mediated cytotoxicity, a microenvironment that presents with an array of immunosuppressive mechanisms differing between tumor types, and a paucity of target antigens with an expression profi le as favorable as that of CD19. Despite an impressive number of investigated targets ( Table 1 ) , few target candidates are tumor specifi c or restricted to the tumor and a "dispensable" normal cell type or a tissue that is sheltered from an immune attack. In this perspective, identifying valid targets to achieve effi cacious tumor rejection while ensuring patient safety is an essential goal that requires further investigation. Nonetheless, several trials using fi rst-and second-generation CARs are under way and listed at ClinicalTrials.gov.
CAR SAFETY
The two main safety concerns associated with the use of CARs are the targeted destruction of normal tissues and cytokine storms associated with large-scale immune responses. The toxicity of the different conditioning regimens used in conjunction with adoptive T-cell therapies is also a signifi cant issue to consider but is beyond the scope of this review.
On-target, Off-tumor Responses
The immune-mediated rejection of normal tissues that express the targeted antigen is referred to as an "on-target, offtumor" response. This occurrence is best illustrated in the B-cell aplasias induced by CD19-targeted CARs (52) (53) (54) . Although B-cell aplasia can be effectively managed by administering intravenous immunoglobulin, such collateral damage may not be tolerable in many other instances. This may for example be the case for her2 ( 61 ) , which is expressed at a low level in several normal tissues, including heart and pulmonary vasculature. Other examples, for which no toxicities have been reported to date, include PSMA, which is highly expressed in castrate-resistant, metastatic prostate cancer but is detected in type II astrocytes, the renal proximal tubule, and the jejunum brush border ( 62 ), ROR1, which is expressed in a subset of leukemias and lymphomas but is also detected in adipocytes ( 63 ) . T cells can be very effective at destroying normal tissues that express the targeted antigen, as exemplifi ed by the ocular and vestibular effects of MART-1-specifi c T cells ( 64 ) and the cholestatic effect of T cells targeted to carbonic anhydrase IX ( 65 ). Whether the very low level expression of antigens such as PSMA and ROR1 on normal tissues will expose these tissues to immune destruction is at present unknown. This problem would be easily resolved if there were truly tumor-specifi c cell surface molecules to target, but such molecules are so far very rare. The identifi cation of restricted CAR targets is therefore a high priority.
Cytokine Storms
The second major concern is that of "cytokine storms" associated with intense antitumor responses mediated by large numbers of activated T cells (53) (54) (55) . These events typically cause high fever and hypotension, potentially resulting in organ failure. Their management may require steroids, vasopressors, and/or supportive therapy delivered in the intensive care unit. Grupp and colleagues ( 66 ) have observed that IL-6 blockade using tocilizumab may be effective in steroid-refractory circumstances without compromising T-cell effi cacy. Unlike many conventional drug-induced side effects, this toxicity cannot be controlled by simply reducing drug dosage, as proliferating T cells will increase in numbers and eventually reach critical levels at which a synchronous cytokine response exceeds tolerability. Split T-cell dosing or short-lived T cells may partially reduce this effect, but more fundamental solutions are needed to reduce and ideally prevent the occurrence of overwhelming T-cell activity.
Emerging Solutions to Improve CAR Safety
Recognizing that CAR-modifi ed T cells are in general well tolerated, their broader use requires having solid strategies to treat or, better, prevent on-target, off-tumor effects and cytokine storms. One therapeutic option is to use suicide genes to have a means to eliminate an excessive response. Herpes simplex virus thymidine kinase ( 67 ) and inducible caspase-9 ( 68 ) are clinically tested systems that could be used to halt deleterious responses ( 69 ) . The drawbacks to this approach are that it is reactive, not preventive, and that active T cells will be eliminated, possibly curtailing the therapy. A better understanding of cytokine storms may offer novel prospects for reducing toxicity without compromising therapy
Research. 
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and limiting the use of corticosteroids ( 66 ) . Signifi cantly, we fi nd, in patients with ALL treated with a CD19-specifi c CD28/ CD3-ζ CAR, that stronger cytokine responses occur in those with large tumor burdens but not in those with minimal residual disease at the time of T-cell infusion, a fi nding that suggests that reducing tumor burden by alternative means before T-cell infusion will reduce the risk of T-cell-induced cytokine-mediated toxicity following a subsequent T-cell infusion (70) . Ultimately, the design of T cells that are effective, highly tumor specifi c, and regulated in their maximal accumulation and activation (so as to preclude toxic cytokine elevation), will represent a valuable advance for the use of CARs. One approach to improve tumor selectivity, based on combinatorial antigen recognition, is reviewed below.
NEW DIRECTIONS IN THE CAR INDUSTRY
New technologies or concepts other than the design of better CARs and their combination with costimulatory ligands, chimeric costimulatory receptors or cytokines, are emerging to broaden or improve the use of CARs. These include improved CAR delivery systems, the design of CARs that recognize intracellular antigens, and combinatorial antigen recognition to increase T-cell specifi city and potency.
CAR Delivery
The mechanics of T-cell transduction are beyond the scope of this review but are briefl y addressed here. CARs began to be investigated in meaningful ways when methods for the transduction of human primary T cells became available in the middle to late 1990s (71) (72) (73) . For the past 15 years, virtually all CAR studies have relied on retroviral vectors, including gammaretroviral and lentiviral vectors ( 74 ) . Most current clinical trials use retroviral vectors derived from murine leukemia virus or human immune defi ciency virus-1. Although retroviral vectors can induce insertional oncogenesis in hematopoietic progenitors ( 75, 76 ) , T cells seem to be far less susceptible to retroviral vector-induced transformation (77) (78) (79) (80) . Transposases, which also provide random vector integration ( 81 ) , are starting to be evaluated in the context of CAR therapy ( 82 ) . The relative advantages and disadvantages of these different integrating systems have not yet been elucidated but will hinge on CAR expression levels, silencing over time, safety features, ease of manufacturing and usage, and cost. Although T-cell transformation secondary to insertional mutagenesis has not been reported to date, site-directed vector integration into genomic safe harbors ( 83 ) may eventually enable the achievement of long-term CAR expression without any risk of insertional oncogenesis. Alternative approaches that do not rely on transgene integration, which use RNA electroporation ( 84, 85 ) or cell surface conjugation ( 86 ) , result in transient CAR expression, precluding effective T-cell persistence beyond a week or two. The usefulness of transiently CAR-expressing T cells, which would presumably require multiple infusions to provide meaningful tumor responses but may reduce destruction of normal tissues or prevent T-cell accumulation to levels that increase the risk of cytokine storms, remains to be established.
Another key aspect of CAR delivery is the addressee and identifying which T cells, expanded under which conditions, are better suited for optimal tumor eradication. As stated above, this topic is beyond the scope of this review, recognizing that different T-cell subsets (CD4 + or CD8 + αβ T cells, γδ T cells, naïve T cells, central memory T cells, effector memory T cells, virus-specifi c T cells, and the recently described stemlike memory T cells; refs. 87, 88 ) warrant further investigation to delineate whether different CAR designs are best suited for different T-cell types. CARs are also functional in Tregs ( 89 ) and in the progeny of transplanted T-cell progenitors ( 90 ) .
CAR-like TCRs and TCR-like CARs
The transfer of TCRs into T cells poses two particular challenges that CARs elude: the risk of mispairing between endogenous and transduced TCR chains ( 91 ) and competition for rate-limiting CD3 complex ( 92 ) , which is required for TCR signaling. Several approaches have been proposed to prevent TCR chain mispairing, including partial murinization of the constant regions, the addition of disulfi de bonds, and altering the knob-in-hole directional interaction between constant regions. Another approach is to add signaling domains to the intracellular portions of the transduced TCR ( 93 ) , similarly to fi rst-generation CARs, which Sebestyén and colleagues and Roszik and colleagues showed could at once avert TCR mispairing and reduce association with CD3 ( 93, 94 ) .
Conversely, HLA-peptide complexes can be targeted by antibody structures that mimic TCR recognition. CARs may be advantageous in this regard as they neither interfere nor compete with the native TCR and CD3 and can be further endowed with costimulatory capabilities. Human Fab fragments specifi c to peptide/MHC molecules have been derived from phage display libraries ( 95 ) . Although many preferentially bind to MHC ( 96 ) , some high-affi nity Fabs with greater binding affi nity for the peptide have been generated and shown by crystallographic analysis to have a binding footprint to MHC/peptide complexes similar to that of TCRs ( 97 ) . The therapeutic potential and toxicity of these TCR-like CARs remain to be established.
Combinatorial Antigen Recognition
T cells may also be rendered more tumor-selective through combinatorial antigen recognition. We recently described a strategy that integrates combinatorial antigen recognition, split signaling, and, critically, balanced strength of T-cell activation and costimulation to generate T cells that eliminate target cells that express a combination of antigens while sparing cells that express each antigen individually ( 98 ) . With this approach, T-cell activation requires TCR or CARmediated recognition of one antigen, whereas costimulation is independently mediated by a CCR ( 33 ) specifi c for a second antigen. To achieve tumor selectivity, we diminished the efficiency of T-cell activation to a level where it was ineffective without rescue provided by simultaneous CCR recognition of the second antigen ( 99 ) . Novel approaches to enforce tumor specifi city in the face of a dearth of truly unique target antigens are an important direction for future immunotherapies.
PERSPECTIVES
While a number of important biologic questions remain to be addressed, including optimizing CAR signaling, defi ning optimal targets, working out optimal combinatorial strategies, identifying the best and most practical processes for T-cell 
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subset selection and T-cell manufacturing, and reducing T-cellmediated toxicity and the toxicity of host conditioning, the fi rst clinical successes of CAR therapy are being registered. The prospect of meeting the challenging premise of adoptive T-cell therapy-to achieve specifi c tumor destruction with one or few T-cell infusions and limited collateral damage to normal tissues-may be within reach. The targeting of B-cell malignancies through CD19 has emerged as the paradigm for the CAR fi eld. At present, it also stands as an exception. The identifi cation of safe targets in a broad range of tumor types, eventually in combinatorial fashion, and harnessing CAR technology for the treatment of solid tumors, are future challenges for all adoptive T-cell therapies including those using CARs. As this review aims to convey, many exciting strategies are in the pipeline, and as many reasons to be optimistic about the prospects for CAR therapies. Providing access to targeted T-cell therapies to all medical centers and their patients will pose additional biologic, logistical, and economic challenges, which are beyond the scope of this review. The fact that models for broad access to targeted T-cell therapies are increasingly discussed is testimony to the therapeutic potential and rising credibility of CARs.
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